Cadrenal Therape Stock Price, News & Analysis

Cadrenal Therapeutics (Nasdaq: CVKD), a biopharmaceutical company focused on anticoagulation therapy, will participate in the virtual Lytham Partners Fall 2025 Investor Conference on September 30, 2025.

The company's webcast presentation is scheduled for 3:30 p.m. ET and will be accessible through the conference website. Management will also be available for one-on-one meetings with investors throughout the event.

Cadrenal Therapeutics (Nasdaq: CVKD) has acquired eXIthera Pharmaceuticals' portfolio of Factor XIa inhibitors, significantly expanding its anticoagulation pipeline. The acquisition includes frunexian, a Phase 2-ready intravenous Factor XIa inhibitor, and EP-7327, an IND-ready oral Factor XIa inhibitor.

The deal positions Cadrenal as the only company developing both a novel vitamin K antagonist (tecarfarin) and Factor XIa inhibitors, targeting the $38 billion global anticoagulation market. The acquisition terms include milestone payments up to $15 million and future royalties. Sichuan Haisco Pharmaceuticals maintains rights to frunexian in China, with Cadrenal receiving royalties on future Chinese sales.

Cadrenal Therapeutics (NASDAQ:CVKD) has reported its Q2 2025 financial results and announced strategic plans for tecarfarin clinical trials. The company will initiate trials for patients with End-Stage Kidney Disease (ESKD) transitioning to dialysis, leveraging tecarfarin's orphan drug and fast-track designations.

Key financial metrics include R&D expenses of $1.1M (down from $1.3M in Q2 2024), G&A expenses of $2.7M (up from $1.2M), and a net loss of $3.7M (increased from $2.4M). Cash position stands at $5.6M as of June 30, 2025.

Operational highlights include successful technical transfer of tecarfarin manufacturing to a U.S. CDMO site, completion of clinical drug product manufacturing, and inclusion in Russell indexes. The company continues exploring development partnerships while focusing on addressing critical anticoagulation therapy gaps.

Cadrenal Therapeutics (Nasdaq: CVKD) has announced plans to initiate clinical trials for tecarfarin, its lead late-stage drug candidate, targeting patients with End-Stage Kidney Disease (ESKD) transitioning to dialysis. The trials, set to begin in late 2025, will include patients both with and without atrial fibrillation (AFib).

Tecarfarin, which has received orphan drug and fast-track designations for ESKD patients with AFib, represents a potential breakthrough as a next-generation Vitamin K antagonist. The drug's unique metabolism pathway is not significantly affected by kidney impairment, addressing a critical treatment gap for dialysis patients who are typically excluded from clinical trials due to high risk profiles.

Cadrenal Therapeutics (NASDAQ: CVKD) has revealed new third-party research highlighting the significant medical and economic challenges faced by LVAD patients requiring chronic anticoagulation. The research, conducted by Guidehouse, shows substantial hospitalization costs for major bleeding events: $54,100 for intracranial hemorrhage, $26,900 for gastrointestinal bleeds, and $36,600 for other major bleeds. The company's Phase 3-ready drug tecarfarin is positioned as a potential alternative to warfarin for LVAD patients. Tecarfarin's key advantage lies in its novel metabolic pathway through a single enzyme (CES2), which may reduce drug interactions, dietary complications, and adverse bleeding or thrombotic events compared to warfarin's multiple metabolic pathways.

Cadrenal Therapeutics (NASDAQ: CVKD), a biopharmaceutical company focused on cardiovascular disease treatments, announced its participation in the BIO International Convention 2025, scheduled for June 16-19 in Boston. The company's executive team will engage in one-on-one meetings with investors and potential partners to discuss their strategic direction and provide updates on tecarfarin, their lead drug candidate. The BIO International Convention is recognized as the largest biotechnology event globally, attracting over 20,000 industry leaders from the life sciences sector. Interested parties can schedule meetings through the Conference portal or by contacting the company's Investor Relations.

Cadrenal Therapeutics (NASDAQ: CVKD) has achieved key manufacturing milestones for tecarfarin, its lead drug candidate. The company successfully completed the technical transfer and manufacturing of tecarfarin drug substance under cGMP standards at a U.S.-based CDMO facility earlier this year. The manufacturing of the drug product candidate is currently in progress.

Tecarfarin is a novel oral vitamin K antagonist (VKA) anticoagulant designed to address unmet needs in anticoagulation therapy for patients with cardiovascular disease. The manufacturing progress represents a significant step in supporting the company's clinical development strategy.

Cadrenal Therapeutics (NASDAQ: CVKD) reported its Q1 2025 financial results and corporate updates. Key highlights include: appointment of Dr. James Ferguson as Chief Medical Officer, a successful FDA Type D Meeting providing guidance for tecarfarin's Phase 3 trial, and a Collaboration Agreement with Abbott for the TECH-LVAD trial. The company completed technical transfer of tecarfarin manufacturing to a U.S. CDMO and conducted market research showing growth potential in the LVAD market. Financial results show R&D expenses of $1.7M (up from $0.6M in Q1 2024), G&A expenses of $2.3M (up from $1.1M), and a net loss of $3.8M. Cash position stands at $7.3M as of March 31, 2025, down from $10.0M at year-end 2024.

Cadrenal Therapeutics (CVKD) has announced its participation in the inaugural Centri Capital Conference, scheduled to take place at Nasdaq in New York City on April 22, 2025. Chairman and CEO Quang X. Pham will deliver a company presentation and provide updates on tecarfarin, the company's lead asset.

Tecarfarin, a Phase 3-ready oral vitamin K antagonist anticoagulant, is being developed to address unmet needs in anticoagulation therapy. The conference will bring together capital markets representatives and investment community members, focusing on companies innovating in healthcare and life sciences sectors.